Esophageal Fully Covered Metal Stents in Caustic Strictures Study

Not Applicable

Completed

• Conditions: Refractory Benign Esophageal Strictures Caused by Caustic Ingestion
• Interventions: Device: Metal Stent (WallFlex™ Esophageal RX)

• Registration Number: NCT01899300
• Lead Sponsor: Boston Scientific Corporation

Brief Summary

The purpose of this study is to establish clinical proof of concept of temporary indwell of the WallFlex™ Esophageal Fully Covered Metal Stent (FCMS) for the treatment of refractory benign esophageal strictures caused by caustic ingestion.

Detailed Description

The purpose of this study is to establish clinical proof of concept of temporary indwell of the WallFlex™ Esophageal Fully Covered Metal Stent (FCMS) for the treatment of refractory benign esophageal strictures caused by caustic ingestion. Also to collect data in support of a hypothesis required to prospectively document the safety and effectiveness of temporary indwell of the WallFlex™ Esophageal Fully Covered Metal Stent (FCMS) compared to repeated Bougie Dilation for the treatment of refractory benign esophageal strictures caused by caustic ingestion.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2013-06-28
• Study First Submitted QC: 2013-07-12
• Study First Posted: 2013-07-15
• Study Start: 2015-03
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Results First Submitted: 2017-06-29
• Status Verified: 2021-01
• Results First Submitted QC: 2021-01-25
• Last Update Submitted: 2021-01-25
• Results First Posted: 2021-02-12
• Last Update Posted: 2021-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

1. Availability of medical history pertaining to dysphagia score prior to and during the preceding SECSER.
2. Availability of patient history pertaining to weight prior to and at completion of SECSER.
3. Benign esophageal stricture caused by caustic ingestion 12 or more weeks prior to enrollment.
4. Single esophageal stricture or multiple esophageal stricture over a length < 6 cm.
5. Having completed the SECSER consisting of 3 dilations intended to reach 15 mm each, separated by 2 weeks, followed by 3 dilations intended to reach 15 mm each with steroid injections, separated by 2 weeks. The dilations may be performed using Bougie or balloon dilation at the discretion of the investigator.
6. Refractory stricture defined as recurrence of stricture with associated dysphagia within 6 months after completion of SECSER.
7. Dysphagia score of 2 (ability to swallow semi-solid foods), 3 (ability to swallow liquids only) or 4 (unable to swallow liquids) at baseline.
8. Unable to pass a standard endoscope (approximately 9.8 mm diameter).
9. Age 18 years or older.
10. Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Read More

Exclusion Criteria

1. Stricture within 2 cm of the upper esophageal sphincter.
2. Concomitant Esophageal ulcerations.
3. Prior esophageal stent placements.
4. Concurrent gastric and/or duodenal obstruction.
5. Patients with prior full or partial gastrectomy.
6. Sensitivity to any components of the stent or delivery system.
7. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.
8. Participation in a clinical trial evaluating an investigational device within 3 months prior to enrollment in this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Metal Stent	Metal Stent (WallFlex™ Esophageal RX)	The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.

Primary Outcome Measures

Name	Time	Method
Clinical Success	From stent placement on day 0 to 6 months after stent removal	Clinical success consisting of stent tolerability and adequate ability to sustain nutrition to 6 months after stent removal. Stent tolerability defined as absence of pain-related stent removal. Adequate ability to sustain nutrition defined as absence of dysphagia-related reintervention.

Secondary Outcome Measures

Name	Time	Method
Stent Removal Success	Stent removal at Week 8 (±7 days)	Number of participants with successful stent removal. Successful stent removal defined as the ability to remove the stent endoscopically without serious stent removal related complications.
Dysphagia Score During Stent Treatment Compared to Score During Proceeding Standardized Esophageal Caustic Stricture Endoscopic Treatment Regimen (SECSER)	Dysphagia score at SECSER was measured prior to baseline. Dysphagia score during stent treatment was measured from stent placement on day 0 to end of study at Week 32	Change in Dysphagia score during stent treatment compared to dysphagia score during proceeding standardized esophageal caustic stricture endoscopic treatment regimen (SECSER). Change value was calculated as dysphagia score during stent treatment (Day 2, Week 1, Week 2, and thereafter every 2 weeks until end of study at Week 32 minus dysphagia score at SECSER.; Dysphagia is reported using Dysphagia Scoring System (see scoring system below) with higher score meaning a worse outcome.; 0. = ability to eat a normal diet; 1. = ability to eat some solids; 2. = ability to eat some semisolids only; 3. = ability to swallow liquids only; 4. = complete dysphagia
Number of Stent Migration With or Without Related Adverse Events	From stent placement on Day 0 to end of study at Week 32.	Number of stent migration with or without Related adverse events (AE). Stent migration is defined as any proximal or distal migration of stent.
Stent Placement Success	Stent placement on Day 0	Number of participants with successful stent placement. Successful stent placement defined as the ability to deploy the stent in satisfactory position across the stricture
Change in Patient's Report on Pain Compared to Baseline	From baseline to stent removal at Week 8 (±7 days)	Change in Patient's report on pain compared to Baseline at Day 2, Week 1, Week 2, Week 4, Week 6, and Thereafter every 2 weeks until stent removal at Week 8. Pain is reported on the VAS Pain Score scale from 0 (0 being No Pain) to 10 (10 being Worst Pain Ever). Higher score means a worse outcome.; If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.
Time to Recurrence of Stricture	From stent placement on Day 0 to end of study at Week 32.	Time to Recurrence of Stricture, Defined as Inability of a Normal Diameter Gastroscope (9.8 mm) to Pass the Stricture
Change in Patient Weight Compared to Baseline	From stent placement on Day 0 to end of study at Week 32.	Change in Patient Weight Compared to Baseline: Day 2, Week 1, Week 2, Week 4, Week 6, Week 8, and Thereafter Every 2 Weeks Until End of Study at Week 32. Positive value means increase in weight and negative value means decrease in weight.
Change in Patient Weight During Stent Treatment Compared to Weight Gain During Preceding SECSER	From stent placement on Day 0 to end of study at Week 32.	Change in patient weight during stent treatment (day 2, week 1, week 2, week 4, week 6, week 8, and thereafter every 2 weeks until end of study at week 32) compared to preceding standardized esophageal caustic stricture endoscopic treatment regimen (SECSER). Positive value means increase in weight and negative value means decrease in weight.
Change of Pain Medication Intake From Baseline	From baseline to stent removal at Week 8 (±7 days)	Change of pain medication intake from baseline at Day2, Week1, Week2, and thereafter every 2 weeks until stent removal
Change in Dysphagia Score Compared to Baseline	From stent placement on day 0 to end of study at Week 32.	Change in dysphagia score compared to Baseline at Day 2, Week 1, Week 2, Week 4, Week 6, Week 8, and thereafter every 2 weeks until end of study at Week 32. Change value was calculated as dysphagia score measured during stent treatment minus dysphagia score at Baseline.; Dysphagia is reported using Dysphagia Scoring System (see scoring system below) with higher score meaning a worse outcome.; 0 = ability to eat a normal diet; 1. = ability to eat some solids; 2. = ability to eat some semisolids only; 3. = ability to swallow liquids only; 4. = complete dysphagia
Change in Quality of Life (QOL) Compared to Baseline	From stent placement on Day 0 to end of study at Week 32	Change in overall Quality of Life (QOL) health score compared to Baseline at Day 2, Week 1, Week 2, Week 4, Week 6, Week 8, and thereafter every 2 weeks until end of study at Week 32. QOL Overall Health Score is measured on a scale of 0 to 100, with 0 meaning the worst health you can imagine and 100 meaning the best health you can imagine. Higher score means a better outcome.
Occurrence of Adverse Events	From stent placement on Day 0 to end of study at Week 32.	Occurrence of Adverse Events Related to the Stent and/or the Stent Placement or Stent Removal Procedure and of All Serious Adverse Events Throughout the Duration of the Study

Trial Locations

Locations (2)

Asian Institute of Gastroenterology; 🇮🇳 Hyderabad, India

Postgraduate Institute of Medical Education and Research; 🇮🇳 Chandigarh, India